On October 2, 2025 Phost’in Therapeutics, a clinical-stage biotechnology company focused on the development of N-glycosylation inhibitors and the Fondazione Gianni Bonadonna, which provides scientific contribution and independent support, reported that it will jointly present a poster on interim clinical data from the PhAST trial at the European Society for Medical Oncology (ESMO) (Free ESMO Whitepaper) Annual Congress 2025, held October 17–21 in Berlin, Germany (Press release, Phost’in, OCT 2, 2025, View Source [SID1234656403]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!